Journal Mobile Options
Table of Contents
Vol. 140, No. 2, 2006
Issue release date: May 2006
Int Arch Allergy Immunol 2006;140:89–95

Infectious Burden as a Determinant of Atopy – A Comparison between Adults in Finnish and Russian Karelia

von Hertzen L.C. · Laatikainen T. · Mäkelä M.J. · Jousilahti P. · Kosunen T.U. · Petäys T. · Pussinen P.J. · Haahtela T. · Vartiainen E.
aSkin and Allergy Hospital and bDepartment of Oral and Maxillofacial Diseases, Helsinki University Central Hospital, cDepartment of Epidemiology and Health Promotion, National Public Health Institute, and dHaartman Institute and eInstitute of Dentistry, University of Helsinki, Helsinki, Finland

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Evidence of the influence of pathogen exposure on the development of atopy and atopic disease is not unequivocal. We investigated the association between markers of infections and occurrence of atopy among adults in eastern Finland and western Russia, two adjacent areas with profound differences in living conditions and lifestyles. Methods: Randomly selected adults aged 25–54 years from Finland (n = 790) and from Russia (n = 387) participated in the study. Skin prick tests were performed to 11 common airborne allergens, and at least one positive prick reaction was considered to indicate atopy. Antibodies to different pathogens including hepatitis A virus (HAV), Helicobacter pylori, Toxoplasma gondii, herpes simplex virus (HSV), Chlamydia pneumoniae and the periodontal pathogens Porphyromonas gingivalis and Actinobacillus actinomycetemcomitans were measured. Results: In Finland 34.3% and in Russia 23.3% of the study population was atopic (p < 0.001). Seroprevalences to all these pathogens were significantly higher among the Russians. In multivariate logistic regression analysis, only H. pylori was inversely associated with atopy in Russia. A further stepwise analysis revealed that H. pylori alone can explain 32% of the difference in atopy between the countries, and T. gondii, A. actinomycetemcomitans, HSV and C. pneumoniae had a slightly additive effect, whereas, unexpectedly, seropositivity to HAV and, to a lesser extent, P. gingivalis had an opposite effect. The net result of the stepwise analysis showed that 44% of the difference in atopy between the countries could be explained by seropositivity to these seven pathogens. Conclusions: Seropositivity to select pathogens, particularly to H. pylori, could explain a substantial part of the difference in atopy prevalence between Finland and Russia. Exposure to HAV was not associated with protection against atopy in this adult population.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Shaheen SO, Aaby P, Hall AJ, Barker DJ, Heyes CB, Shiell AW, Goudiaby A: Measles and atopy in Guinea-Bissau. Lancet 1996;347:1792–1796.
  2. Matricardi PM, Rosmini F, Ferrigno L, Nisini R, Rapicetta M, Chionne P, Stroffolini T, Pasquini P, D’Amelio R: Cross-sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus. BMJ 1997;314:999–1003.
  3. Shirakawa T, Enomoto T, Shimazu S, Hopkin JM: The inverse association between tuberculin responses and atopic disorder. Science 1997;275:77–79.
  4. Matricardi PM, Rosmini F, Riondino S, Fortini M, Ferrigno L, Rapicetta M, Bonini S: Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. BMJ 2000;320:412–417.
  5. Matricardi PM, Rosmini F, Panetta V, Ferrigno L, Bonini S: Hay fever and asthma in relation to markers of infection. J Allergy Clin Immunol 2002;110:381–387.
  6. Linneberg A, Ostergaard C, Tvede M, Andersen LP, Nielsen NH, Madsen F, Frolund L, Dirksen A, Jorgensen T: IgG antibodies against microorganisms and atopic disease in Danish adults: the Copenhagen Allergy Study. J Allergy Clin Immunol 2003;111:847–853.
  7. Kosunen TU, Höök-Nikanne J, Salomaa A, Sarnas S, Aromaa A, Haahtela T: Increase of allergen-specific immunoglobulin E antibodies from 1973 to 1994 in a Finnish population and a possible relationship to Helicobacter pylori infections. Clin Exp Allergy 2002;32:373–378.
  8. Law M, Morris JK, Wald N, Luzynska C, Burney P: Changes in atopy over a quarter of century, based on cross sectional data at three time periods. BMJ 2005;330:1187–1188.
  9. Uter W, Stock C, Pfahlberg A, Guillén-Grima F, Aguinaga-Ontoso I, Brun-Sandiumenge C, Krämer A: Association between infections and signs and symptoms of ‘atopic’ hypersensitivity – results of a cross-sectional survey among first-year university students in Germany and Spain. Allergy 2003;58:580–584.
  10. Bodneer C, Anderson WJ, Reid TS, Godden DJ: Childhood exposure to infection and risk of adult onset wheeze and atopy. Thorax 2000;55:383–387.
  11. Scrivener S, Yemaneberhan H, Zebenigus M, Tilahun D, Girma S, Ali S, McElroy P, Custovic A, Woodcock A, Pritchard D, Venn A, Britton J: Independent effects of intestinal parasite infection and domestic allergen exposure on risk of wheeze in Ethiopia: a nested case-control study. Lancet 2001;358:1493–1499.
  12. Gonzalez-Quintela A, Gude F, Boquete O, Aguilera A, Rey J, Meijide LM, Fernandez-Merino MC, Vidal C: Association of hepatitis A virus infection with allergic sensitization in a population with high prevalence of hepatitis A virus exposure. Allergy 2005;60:98–103.
  13. Umetsu DT, McIntire JJ, DeKruyff RH: TIM-1, hepatitis A virus and the hygiene theory of atopy: association of TIM-1 with atopy (review). J Pediatr Gastroenterol Nutr 2005;40(suppl 1):S43.
  14. Vartiainen E, Petäys T, Haahtela T, Jousilahti P, Pekkanen J: Allergic diseases, skin prick test responses, and IgE levels in North Karelia, Finland, and the Republic of Karelia, Russia. J Allergy Clin Immunol 2002;109:643–648.
  15. Pussinen PJ, Vilkuna-Rautiainen T, Alfthan G, Mattila K, Asikainen S: Multiserotype enzyme-linked immunosorbent assay as a diagnostic aid for periodontitis in large-scale studies. J Clin Microbiol 2002;40:512–518.
  16. McIntire JJ, Umetsu SE, Macaubas C, Hoyte E, Cinnioglu C, Cavalli-Sforza L, Barsh G, Hallmayer J, Underhill P, Risch N, Freeman G, DeKruyff R, Umetsu D: Hepatitis A virus link to atopic disease: association of TIM-1 with atopy. Nature 2003;425:576.
  17. Swenson P: Hepatitis viruses; in Balows A, Hausler W Jr, Herrmann K, Isenberg H, Shadomy J (eds): Manual of Clinical Microbiology. Washington, American Society for Microbiology, 1991, pp 959–983.
  18. Redpath S, Ghazal P, Gascoigne RJ: Hijacking and exploitation of IL-10 by intracellular pathogens. Trends Microbiol 2001;9:86–92.
  19. Mills KH, McGuirk P: Antigen-specific regulatory T cells – their induction and role in infection. Semin Immunol 2004;16:107–117.
  20. Hawrylowicz CM, O’Garra A: Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 2005;5:271–283.
  21. Umetsu DT, Akbari O, DeKruyff RH: Regulatory T cells control the development of allergic disease and asthma. J Allergy Clin Immunol 2003;112:480–487.
  22. Kullberg MC, Jankovic D, Gorelick PL, Caspar P, Letterio JJ, Cheever AW, Sher A: Bacteria-triggered CD4+ T regulatory cells suppress Helicobacter hepaticus-induced colitis. J Exp Med 2002;196:505–515.
  23. Kolho ML, Haapaniemi A, Haahtela T, Rautelin H: Helicobacter pylori and specific immunoglobulin E antibodies to food allergens in children. J Pediatr Gastroenterol Nutr 2005;40:180–183.
  24. Zevering Y: Vaccine against Helicobacter pylori? Ann Med 2001;33:156–166.
  25. Blaser MJ: Helicobacters are indigenous to the human stomach: duodenal ulceration is due to changes in gastric microecology in the modern era. Gut 1998;43:721–727.
  26. Normann E, Gnarpe J, Gnarpe H, Wettergren B: Chlamydia pneumoniae infection predicts a reduced risk for subsequent atopic disease. Acta Pediatr 2005;94:705–710.
  27. von Hertzen LC: Role of persistent infection in the control and severity of asthma – focus on Chlamydia pneumoniae. Eur Respir J 2002;19:546–556.
  28. von Hertzen L, Töyrylä M, Ginishanov A, Bloigu A, Leinonen M, Saikku P, Haahtela T: The relationship between asthma, atopy and Chlamydia pneumoniae antibodies in adults. Clin Exp Allergy 1999;29:522–528.
  29. Arvin A, Prober CG: Herpes simplex viruses; in Balows A, Hausler W Jr, Herrmann K, Isenberg H, Shadomy J (eds): Manual of Clinical Microbiology. Washington, American Society for Microbiology, 1991, pp 822–828.
  30. Nilsson C, Linde A, Montgomery SM, Gustafsson L, Näsman P, Troye Blomberg M, Lilja G: Does early EBV infection protect against IgE sensitization? J Allergy Clin Immunol 2005;116:438–444.
  31. Slots J: Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in periodontal disease: introduction. Periodontology 2000;1999;20:7–13.
  32. Rook GA, Adams V, Hunt J, Palmer R, Martinelle R, Brunet LR: Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders. Springer Semin Immunopathol 2004;25:237–255.
  33. Björksten B: Effects of intestinal microflora and the environment on the development of asthma and allergy. Springer Semin Immunopathol 2004;25:257–270.
  34. Herz U, Lacy P, Renz H, Erb K: The influence of infections on the development and severity of allergic disorders. Curr Opin Immunol 2000;12:632–640.
  35. Liu AH: Endotoxin exposure in allergy and asthma: reconciling a paradox. J Allergy Clin Immunol 2002;109:379–392.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50